Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paltusotine in Carcinoid Syndrome
NCT07087054Phase 3Active, not recruiting
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in Carcinoid Syndrome (CS) comparing Paltusotine 80 mg daily with Placebo (2 arms). Primary endpoint: Number of flushing episodes per day at 12 weeks. Started Nov 2025; status: active, not recruiting.
02
Drugs
paltusotine
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT07087054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07087054.